Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OLTIPRAZ CHEMOPREVENTION TRIAL IN QIDONG, JIANGSU PROVINCE, PEOPLES-REPUBLIC-OF-CHINA
Autore:
ZHANG BC; ZHU YR; WANG JB; WU Y; ZHANG QN; QIAN GS; KUANG SY; LI YF; FANG X; YU LY; DEFLORA S; JACOBSON LP; ZARBA A; EGNER PA; HE X; WANG JS; CHEN BB; ENGER CL; DAVIDSON NE; GORDON GB; GORMAN MB; PROCHASKA HJ; GROOPMAN JD; MUNOZ A; HELZLSOUER KJ; KENSLER TW;
Indirizzi:
JOHNS HOPKINS SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,615 N WOLFE ST BALTIMORE MD 21205 JOHNS HOPKINS SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI BALTIMORE MD21205 QIDONG LIVER CANC INST QIDONG JIANGSU PEOPLES R CHINA SHANGHAI CANC INST SHANGHAI PEOPLES R CHINA SHANGHAI MED UNIV SHANGHAI 200032 PEOPLES R CHINA UNIV GENOA,INST HYG & PREVENT MED I-16132 GENOA ITALY JOHNS HOPKINS SCH HYG & PUBL HLTH,DEPT EPIDEMIOL BALTIMORE MD 00000 JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR BALTIMORE MD 21205 MEM SLOAN KETTERING CANC CTR,MOL PHARMACOL & THERAPEUT PROGRAM NEW YORK NY 10021
Titolo Testata:
Journal of cellular biochemistry
, , anno: 1997, supplemento:, 28-29
pagine: 166 - 173
SICI:
0730-2312(1997):<166:OCTIQJ>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-SUPPRESSOR GENE; HUMAN HEPATOCYTES; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOLE-3-THIONE OLTIPRAZ; HEPATOCELLULAR-CARCINOMA; OF-CHINA; AFLATOXIN; INDUCTION; CANCER; RISK; DITHIOLETHIONES;
Keywords:
AFLATOXIN B-1; AFLATOXIN ALBUMIN ADDUCTS; BIOMARKERS; ENZYME INDUCTION; GLUTATHIONE S-TRANSFERASES; HEPATOCELLULAR CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
B.C. Zhang et al., "OLTIPRAZ CHEMOPREVENTION TRIAL IN QIDONG, JIANGSU PROVINCE, PEOPLES-REPUBLIC-OF-CHINA", Journal of cellular biochemistry, 1997, pp. 166-173

Abstract

Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in aflatoxin metabolic activation and detoxication. In 1995, a randomized, placebo-controlled, double-blind intervention was conducted in residents of Qidong, People's Republic of China, who are at high risk for exposure to aflatoxin and development of hepatocellular carcinoma. The major study objectives were to define a dose and schedule for oltipraz that would reduce levels of aflatoxin biomarkers in biofluids of the participants, and to further characterize dose-limiting side effects. Two hundred thirty-four healthy eligible individuals, including those infected with HBV, were randomized to receive either 125 mg oltipraz daily, 500 mg oltipraz weekly,or placebo. Blood and urine specimens were collected to monitor potential toxicities and evaluate biomarkers over the 8-week intervention and subsequent 8-week follow-Lip periods. Overall, compliance in the intervention was excellent; approximately 85% of the participants completed the study. Objective evaluation of adverse events was greatly facilitated by inclusion of a placebo arm in the study design. A syndrome involving numbness, tingling, and pain in the fingertips was the only event that occurred more frequently among the active groups (18 and 14% of the daily 125 mg and weekly 500 mg arms, respectively) compared to placebo (3%). These symptoms were reversible and could be relieved with non-steroidal antiinflammatory agents. A more complete understanding of the chemopreventive utility of oltipraz awaits completion of an assessment of the efficacy of oltipraz in modulating levels of aflatoxin biomarkers. (C) 1998 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 10:11:02